title: Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
abstract: The plasminogen activation system is considered to play an important role in cancer growth and metastasis. Both plasminogen activators (PAs) and their fast-acting inhibitors are produced in tumor cells and their surrounding tissues. In order to clarify the influence of the existence of malignant tumor in urinary tract on the systemic fibrinolytic activity, we designed a study in which we compared the plasma levels of PAs and their inhibitors between before and after radical resection of tumors. Fourteen patients with renal cell carcinoma and 14 patients with transitional cell carcinoma participated in the study. In both groups, plasma levels of tissue-type plasminogen activator and urokinase-type plasminogen activator before the operation were higher than those 15 days after operation. The plasma level of plasminogen activator inhibitor 1 (PAI-1), however, did not change after the operation in the renal cell carcinoma group, and it decreased slightly in the transitional cell carcinoma group although it was not significant. When these values of the groups with or without metastasis were compared to other organs or lymph nodes, the PAI-1 level before operation was significantly higher in the group with metastasis than that without metastasis. In the three groups divided by the degree of atypia, PAI-1 level in the most atypical group was the highest. These results suggest that the fibrinolytic system in the plasma of cancer patients may play an important role in tumor growth and metastasis.
authors.affiliation: Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Bashar
authors.forename: T
authors.initials: T
authors.lastname: Urano
authors.forename: K
authors.initials: K
authors.lastname: Fukuta
authors.forename: M H
authors.initials: MH
authors.lastname: Pietraszek
authors.forename: M
authors.initials: M
authors.lastname: Hata
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Kawabe
authors.forename: Y
authors.initials: Y
authors.lastname: Takada
authors.forename: A
authors.initials: A
authors.lastname: Takada
mesh_terms: D002292:Carcinoma, Renal Cell / Q000201:enzymology* / Q000556:secondary / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000201:enzymology* / Q000556:secondary / Q000601:surgery; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000201:enzymology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D010959:Tissue Plasminogen Activator / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*; D014571:Urologic Neoplasms / Q000201:enzymology* / Q000601:surgery
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator